When to order a biopsy to characterise a metastatic relapse in breast cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Foukakis, T ^a   Astrom G ^b   Lindstrom L ^a   Hatschek, T ^a   Bergh, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biopsy; Breast cancer; Heterogeneity; Predictive biomarker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HORMONE DEFICIENCY; HORMONE DETERMINATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR BIOPSY; VISCERAL METASTASIS;

BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84866759069     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds297     Document Type: Article

References (44)

1. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg 1979; 137: 260-262.
2. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 479-485.
3. Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 252-257.
4. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20: 1953-1958.
5. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
6. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009; 27: 5278-5286.
7. Beslija S, Bonneterre J, Burstein HJ et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20: 1771-1785.
8. Peterson LM, Mankoff DA, Lawton T et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008; 49: 367-374.
9. Sandberg D, Wennborg A, Feldwisch J et al. First-in-human whole-body HER2-receptor mapping using Affibody molecular imaging. In San Antonio Breast Cancer Symposium, San Antonio. Cancer Res 2011; 71: 273s.
10. Broom RJ, Tang PA, Simmons C et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009; 29: 1557-1562.
11. Curigliano G, Bagnardi V, Viale G et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011; 22: 2227-2233.
12. Guarneri V, Giovannelli S, Ficarra G et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 838-844.
13. Lindström L, Karlsson E, Wilking U et al. Clinically used breast cancer markers such as ER, PR and HER2 are instable throughout tumor progression. J Clin Oncol 2012; 30: 2601-2608.
14. Lower EE, Glass EL, Bradley DA et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90: 65-70.
15. Nedergaard L, Haerslev T, Jacobsen GK. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. APMIS 1995; 103: 20-24.
16. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20: 1499-1504.
17. Wang B, Guan ZZ, Liu DG et al. Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer. Ai Zheng 2004; 23: 1710-1713.
18. Wu JM, Fackler MJ, Halushka MK et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008; 14: 1938-1946.
19. Edgerton SM, Moore D, II, Merkel D et al. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003; 11: 214-221.
20. Gancberg D, Di Leo A, Cardoso F et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-1043.
21. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: 1763-1769.
22. Lipton A, Leitzel K, Ali SM et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005; 104: 257-263.
23. Lower EE, Glass E, Blau R et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-306.
24. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000; 30: 259-265.
25. Meng S, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 9393-9398.
26. Niehans GA, Singleton TP, Dykoski D et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993; 85: 1230-1235.
27. Pectasides D, Gaglia A, Arapantoni-Dadioti P et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006; 26: 647-653.
28. Sekido Y, Umemura S, Takekoshi S et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 2003; 22: 1225-1232.
29. Shimizu C, Fukutomi T, Tsuda H et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000; 73: 17-20.
30. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-5348.
31. Tapia C, Savic S, Wagner U et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007; 9: R31.
32. Wilking U, Karlsson E, Skoog L et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011; 125: 553-561.
33. Zidan J, Dashkovsky I, Stayerman C et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-556.
34. Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30: 593-599.
35. Botteri E, Disalvatore D, Curigliano G et al. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2012; 21: 284-288.
36. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 587-592.
37. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010; 12: R92.
38. Amir E, Clemons M, Purdie CA et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012; 38: 708-714.
39. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
40. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
41. Weigelt B, Hu Z, He X et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65: 9155-9158.
42. Norberg T, Klaar S, Karf G et al. Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort. Cancer Res 2001; 61: 8317-8321.
43. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
44. Cresswell AB, Welsh FK, Rees M. A diagnostic paradigm for resectable liver lesions: to biopsy or not to biopsy? HPB (Oxford) 2009; 11: 533-540.